Corporate ProfileMyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine
approach to discover, develop and commercialize targeted therapies for the treatment of serious
and neglected rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of
heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result
from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision
medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the
two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM,
and dilated cardiomyopathy, or DCM.